First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects

AST-004 is a small-molecule adenosine A1/A3 receptor agonist that has exhibited significant cerebroprotective efficacy in preclinical models of acute ischemic stroke and traumatic brain injury. The primary objectives of this clinical phase I first-in-human study were to evaluate the safety and toler...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Stroke (1970) Ročník 55; číslo 12; s. 2795
Hlavní autoři: Manna, Lisa M, Hernandez, Juan, Hunt, Dawn E, Lakner, Géza, Matson, Mark A, Poe, Russell B, Korinek, William S, Lancey, Robert A, Liston, Theodore E
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.12.2024
Témata:
Adenosine A1 Receptor Agonists - adverse effects
Adenosine A1 Receptor Agonists - pharmacokinetics
Adenosine A3 Receptor Agonists - adverse effects
Adenosine A3 Receptor Agonists - pharmacokinetics
Adult
Brain Injuries, Traumatic - prevention & control
Dose-Response Relationship, Drug
Double-Blind Method
Female
Healthy Volunteers
Humans
Infusions, Intravenous
Male
Middle Aged
Stroke - prevention & control
Triazoles
Young Adult
astrocytes
half-life
humans
stroke
brain injuries, traumatic
ISSN:1524-4628, 1524-4628
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:AST-004 is a small-molecule adenosine A1/A3 receptor agonist that has exhibited significant cerebroprotective efficacy in preclinical models of acute ischemic stroke and traumatic brain injury. The primary objectives of this clinical phase I first-in-human study were to evaluate the safety and tolerability profile of single ascending intravenous doses in healthy subjects. The secondary objectives were to characterize the single-dose pharmacokinetic profiles in plasma, cerebrospinal fluid (CSF), and urine. In part 1 of the study, AST-004 was administered in ascending dose cohorts of 5, 25, 50, 75, and 100 mg, with 6 subjects in each cohort receiving the study drug and 2 receiving placebo. In part 2, all 12 subjects received a 100 mg IV infusion of the study drug followed by a single CSF collection per subject via lumbar puncture at 20, 40, or 60 minutes after infusion. A total of 42 subjects received AST-004, with no severe or serious adverse events observed. Twelve of these subjects experienced a treatment-emergent adverse event, the most frequent across groups being headache. In part 2, pharmacokinetic analyses confirmed that AST-004 was distributed in the CSF, with the CSF-to-plasma ratio increasing over the 3 timepoints sampled. The mean half-life was 1.1 to 1.4 hours for doses of 25 to 100 mg, and the geometric mean maximum plasma concentration obtained in the highest dosing cohort (100 mg) was 2232±428 ng/mL. AST-004 was safe and well-tolerated at plasma concentrations 3 to 8× higher than those associated with significant efficacy in astrocyte's preclinical primate stroke efficacy studies, with CSF concentrations highest at the 60-minute collection timepoint, the last timepoint tested. This study supports additional clinical investigations, including evaluation of an extended infusion to support the phase 2 program in stroke and traumatic brain injury.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1524-4628
1524-4628
DOI:10.1161/STROKEAHA.124.047207